Related Experiment Video
Updated: Jun 21, 2025

Methods to Assess Beta Cell Death Mediated by Cytotoxic T Lymphocytes
Published on: June 16, 2011
RIPK1 is dispensable for cell death regulation in β-cells during hyperglycemia
Önay Veli1, Öykü Kaya1, Ana Beatriz Varanda2
1Department of Translational Genomics, Faculty of Medicine, University of Cologne, Cologne, Germany; Centre for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany; Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany.
Objective:
Receptor-interacting protein kinase 1 (RIPK1) orchestrates the decision between cell survival and cell death in response to tumor necrosis factor (TNF) and other cytokines. Whereas the scaffolding function of RIPK1 is crucial to prevent TNF-induced apoptosis and necroptosis, its kinase activity is required for necroptosis and partially for apoptosis. Although TNF is a proinflammatory cytokine associated with β-cell loss in diabetes, the mechanism by which TNF induces β-cell demise remains unclear.
Methods:
Here, we dissected the contribution of RIPK1 scaffold versus kinase functions to β-cell death regulation using mice lacking RIPK1 specifically in β-cells (Ripk1β-KO mice) or expressing a kinase-dead version of RIPK1 (Ripk1D138N mice), respectively. These mice were challenged with streptozotocin, a model of autoimmune diabetes. Moreover, Ripk1β-KO mice were further challenged with a high-fat diet to induce hyperglycemia. For mechanistic studies, pancreatic islets were subjected to various killing and sensitising agents.
Results:
Inhibition of RIPK1 kinase activity (Ripk1D138N mice) did not affect the onset and progression of hyperglycemia in a type 1 diabetes model. Moreover, the absence of RIPK1 expression in β-cells did not affect normoglycemia under basal conditions or hyperglycemia under diabetic challenges. Ex vivo, primary pancreatic islets are not sensitised to TNF-induced apoptosis and necroptosis in the absence of RIPK1. Intriguingly, we found that pancreatic islets display high levels of the antiapoptotic cellular FLICE-inhibitory protein (cFLIP) and low levels of apoptosis (Caspase-8) and necroptosis (RIPK3) components. Cycloheximide treatment, which led to a reduction in cFLIP levels, rendered primary islets sensitive to TNF-induced cell death which was fully blocked by caspase inhibition.
Conclusions:
Unlike in many other cell types (e.g., epithelial, and immune), RIPK1 is not required for cell death regulation in β-cells under physiological conditions or diabetic challenges. Moreover, in vivo and in vitro evidence suggest that pancreatic β-cells do not undergo necroptosis but mainly caspase-dependent death in response to TNF. Last, our results show that β-cells have a distinct mode of regulation of TNF-cytotoxicity that is independent of RIPK1 and that may be highly dependent on cFLIP.
Insights
Receptor-interacting protein kinase 1 (RIPK1) does not regulate cell death in pancreatic beta cells, even during diabetes. Beta cells primarily undergo caspase-dependent death via tumor necrosis factor (TNF), independent of RIPK1, and are protected by cFLIP.
Area of Science:
- Cell biology
- Immunology
- Endocrinology
Background:
- Receptor-interacting protein kinase 1 (RIPK1) controls cell death pathways like apoptosis and necroptosis, crucial for immune responses and inflammation.
- Tumor necrosis factor (TNF) is implicated in beta cell loss during diabetes, but the precise mechanisms remain unclear.
- Understanding RIPK1's role in beta cell death is vital for diabetes research.
Purpose of the Study:
- To investigate the specific roles of RIPK1's scaffolding and kinase functions in regulating beta cell survival and death.
- To determine if RIPK1 is essential for TNF-induced beta cell demise in the context of diabetes.
- To elucidate the mechanisms underlying beta cell death in response to TNF.
Main Methods:
- Generated mice with RIPK1 specifically deleted in beta cells (Ripk1β-KO) or expressing a kinase-dead RIPK1 mutant (Ripk1D138N).
- Induced diabetes models using streptozotocin and high-fat diet to assess hyperglycemia.
- Analyzed pancreatic islets ex vivo using various cell death stimuli and inhibitors, including TNF, cycloheximide, and caspase inhibitors.
Main Results:
- RIPK1 kinase inhibition or deletion in beta cells did not impact hyperglycemia onset or progression in diabetes models.
- Primary pancreatic islets lacking RIPK1 were resistant to TNF-induced apoptosis and necroptosis.
- Pancreatic islets exhibit high cellular FLICE-inhibitory protein (cFLIP) and low levels of apoptosis (Caspase-8) and necroptosis (RIPK3) components.
- Reducing cFLIP levels sensitized islets to TNF-induced death, fully blocked by caspase inhibition.
Conclusions:
- RIPK1 is dispensable for beta cell death regulation under physiological and diabetic conditions, unlike in other cell types.
- Pancreatic beta cells primarily undergo caspase-dependent death in response to TNF, not necroptosis.
- Beta cells possess a unique TNF-cytotoxicity regulation mechanism independent of RIPK1, heavily reliant on cFLIP.
Related Concept Videos
The Extrinsic Apoptotic Pathway
Insulin: The Receptor and Signaling Pathways
Tissue Renewal without Stem Cells
However, failure of such a system...
Regulation of the Unfolded Protein Response
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are...
PI3K/mTOR/AKT Signaling Pathway

